Page 3 - Diabetes Drug

Going off-patent, key diabetes drug likely to get 50-70% cheaper

Merck's Sitagliptin set to lose patent this month; around 200 brands from 50 firms may enter the market

Glenmark launches fixed-dose combination medication for diabetic patients

Glenmark Pharmaceuticals on Monday said it has launched a novel fixed-dose combination (FDC) of Teneligliptin, with Pioglitazone in India for adults with uncontrolled Type 2 diabetes. Glenmark has launched this FDC under the brand name Zita Plus Pio, which contains Teneligliptin (20 mg) and Pioglitazone (15 mg), to be taken once a day, the company said in a statement. Diabetes is a key area of focus for Glenmark; a pioneer in providing access to the latest treatment options to diabetic patients in India. We are delighted to introduce this novel Zita Plus Pio, which is the first of its kind in India; offering a world-class and affordable treatment option to adult diabetic patients, Glenmark Pharmaceuticals Group Vice President & Head, India Formulations Alok Malik said. Glenmark claimed it is the "first company in India to market the innovative FDC of Teneligliptin + Pioglitazone, which is approved by the DCGI (Drug Controller General of India)" "This fixed-dose combination will be

Zydus gets regulator nod to market generic diabetes drug in American

Zydus Group on Wednesday said it has received final approval from the US health regulator to market diabetes medication Dapagliflozin tablets in the American market. The drug maker has received final approval from the US Food and Drug Administration (USFDA) to market the drug in the strengths of 5 mg and 10 mg. Dapagliflozin is used with a proper diet and exercise programme to control high blood sugar in people with type 2 diabetes. The drug also lowers the risk of heart failure in adults with type 2 diabetes with heart disease. It is also used to lower the risk of further worsening of kidney disease, end-stage kidney disease (ESKD), death due to cardiovascular disease, and hospitalisation for heart failure in adults with chronic kidney disease. Dapagliflozin works by increasing the removal of sugar by kidneys. The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad, Zydus Group stated. The group now has 328 approvals and has so far fi

Glenmark launches unique fixed dose combination drug for diabetes

Glenmark said it has become the first company in the world to launch the fixed dose combination drug in India

Prices of oral diabetes drugs set to fall as patents near expiry date

The diabetes segment has been growing faster than the country's overall drug market

Domestic drug market growth slows top 4.5% in January, some therapies drag

Respiratory segment and anti-infectives contract; Cardiac, anti-diabetic growth rates plummet

New product launches to drive growth for Lupin, US business a key trigger

This should reverse the US underperformance in FY15-20 with margins too moving up sharply

Zydus Cadila gets tentative US FDA approval for generic diabetes drug

Drug firm Zydus Cadila said it has received approval from the US health regulator to market diabetes drug, Empagliflozin and Linagliptin tablets, in the US market

Biocon set for bigger insulin play, aims to reach one in five diabetics

Biocon Biologics CEO says portfolio to form a substantial part of $1 bn revenue target, to roll out insulin Aspart by next year

Lupin gets US FDA approval to market generic diabetes drug in the US

The Mumbai-based company has received a tentative approval from the USFDA for its Empagliflozin tablets

Lupin, Granules India recall 971,000 diabetes drug bottles from US market

As per the USFDA, the companies are recalling the product due to deviation from the current good manufacturing practices

Alembic Pharma gets tentative nod from USFDA for diabetes management drug

The product is therapeutically equivalent to Synjardy tablets of Boehringer Ingelheim Pharmaceuticals, Inc

Unichem, Macleods recall blood pressure, diabetes drugs from US market

Both the recalls by the companies are class III recalls

Coronavirus scare: India may soon run short of antibiotics, diabetes drugs

Pharmaceutical firms seek nod to produce raw material locally

Sweet shake-up: Price relief for diabetes patients as drugs go off patent

The Rs 14,000-crore diabetes drug market in the country is witnessing a churn

Is it possible to keep diabetes under check? Here are a few ways to manage

The most important thing for diabetic patients is to keep their blood sugar level under control to avoid hospitalization

Cipla acquires brand, trademark for anti-diabetic drug Vysov in India

Homegrown pharma major Cipla Ltd on Monday said it has acquired brand name and trademark rights for Vysov for anti-diabetic drug Vildagliptin for the Indian market from Novartis. However, it didn't disclose the acquisition amount. Cipla has been co-marketing Vildagliptin in agreement with Novartis under brand names Vysov and Vysov M (Vildagliptin plus Metformin), the company said in a regulatory filing. "Owing to the increased affordability of Vildagliptin it is more accessible for better management of the disease. Cipla's acquisition of the trademark rights of Vysov will enable us to contribute to easier access of the drug in India," Cipla Executive Vice-President & Head India Business Nikhil Chopra said. The products have witnessed a strong uptake in India for the last couple of years and are currently available across the country, the company said. Vildagliptin is backed by strong clinical data and is therefore a widely prescribed antidiabetic medicine for adults with type-2 ..

French watchdog, pharma firm on trial as Diabetes pill causes 500 deaths

Legal experts have concluded the drug may cause as many as 2,100 deaths in the long term

Glenmark, Torrent Pharma sign agreement to co-market diabetes drug in India

Glenmark launched Remogliflozin, indicated in the treatment of Type 2 Diabetes Mellitus in adults under the brand names Remo and Remozen

New diabetes drug could replace painful insulin jabs

Partial activation can have the benefit of fewer side-effects than full activation